Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05936242
Recruiting Observational

Evaluation of Main Determinants of Postprandial Glucose Response in Type 1 Diabetes

NCT05936242 · tracked via the Priya Life Science Italy tracker
Sponsor
Federico II University
Phase
Observational
Started
2021-05-18
Last updated
2025-09-19

Condition(s) studied

Type 1 Diabetes

Study summary

The goal of this observational study is to explore inter- and intra-individual determinants of postprandial glucose response in patients with type 1 diabetes using continous glucose monitoring (CGM).

Blood samples and anthropometrics will be collected during hospital visit. Participants will be asked to:

* record a seven-day food diary
* complete EPIC food frequency questionnaire
* complete questionnaires on sleep hygiene
* collect a stool sample

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Type 1 Diabetes Exclusion Criteria: * Pregnancy and/or breastfeeding * Other chronic or acute diseases * Use of antibiotics in the past 3 months

Primary outcome measure(s)

  • Postprandial glucose response — Related to 7-days food record
    Postprandial glucose response wil be calculated by the trapezoidal method as the area under the curve above the baseline value (iAUC). The association between iAUC and gut microbiota composition derived from the analysis of faeces samples will be assessed. The association between iAUC and energy intake and dietary composition derived from the analysis of 7-days food record and EPIC will be assessed.

Trial sites (1)

FacilityCityRegionStatus
Federico II University Hospital Naples Italy Recruiting

More Federico II University trials in Italy

Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry) Recruiting
The Role of NIchel and LTPs Sensitization in Functional Gastrointestinal Disorders: the NILT Study Recruiting
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy Recruiting
The Potential Role of Compounds Derived From Ultra-processed Foods in Pathogenesis of Eosinophilic Esophagitis Recruiting
Characterization of Cardiovascular Risk Profile and Therapeutic Management in Patients With Type 2 Diabetes Mellitus in Italy Recruiting

Other trials for the same condition

Type I Diabetes and Non-surgical Periodontal Treatment Active, not recruiting
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes Active, not recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight Active, not recruiting
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) Recruiting
Targeting GLUT1 to Control Autoimmunity in Type 1 Diabetes Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05936242 on ClinicalTrials.gov ↗ ← All trials in Italy